TSXV:CLAS.H - Post by User
Comment by
WORKINMONTANAon Jan 01, 2019 12:18am
111 Views
Post# 29174195
RE:Correction to my last
RE:Correction to my lastDecent breakdown, why does the market sleep on this one?
Jack4000 wrote: Oooops. Zippy the Chimp showed up and checked over my work. Seems I made two errors;
1. The addition of the years was out by 700 million. (Corrected)
2. Forgot we were dealing in USD. (Corrected)
Updated version;
If I remember right the report* said $400 exclusive market year one and adding $100 million per year to 2027 where it is estimated to be $1.3 billion.
If I remember right the report* said $400 exclusive market year one and adding $100 million per year to 2027 where it is estimated to be $1.3 billion. As we're not in year 1 since we have no drug - yet, I moved it to 2020 as year one with, the advance in market going up as per the rationale of the report. (All figures in USD not CD unless specified)
Total $7,600,000 ($10,133,000 CD) over 8 years or $1.4 billion($1.86 CD) per year average. I'm no rocket scientist but with an exclusive market like that and present shares outstanding of 304 million at cap of $18 million, assuming fifty percent profit brings us to a profit of $12.5 per share ($16.6 CD) over that period.
Or, if it's 75% profit then share profit is $18.75 ($25 CD) Average over 8 years and it's $2.34 ($3.12 CD) per share.
In any case, if anybody is worried about dilution, as long as it's helping us get to the start line it's fine with me.
Of course, what do I know, I might be missing something here or, maybe missing everything. Any experts want to chime in?
*"The commercial opportunity for Kalytera’s CBD products for the prevention and treatment of GVHD is large. According to the January 2018 Market Forecast Report by DelveInsight Perspective, the potential market for a successful product for prevention and treatment of GVHD in the 7 major jurisdictions (the U.S., Germany, France, Italy, Spain, the U.K. and Japan) is estimated to be more than USD $408 million in 2018, and could grow to approximately USD $1.3 billion by 2027."